We are live on
!
Find out more
LCM
Lynx1 Capital Management Portfolio holdings
AUM
$633M
1-Year Est. Return
173.22%
This Fund
S&P 500
This Quarter
Est. Return
+8.72%
1 Year Est. Return
+173.22%
3 Year Est. Return
+779.42%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$120M
AUM Growth
+$4.31M
(+3.7%)
Cap. Flow
-$149K
Cap. Flow
% of AUM
-0.12%
Top 10 Holdings %
Top 10 Hldgs %
97.95%
Holding
14
New
1
Increased
8
Reduced
4
Closed
1
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
MRUS
Merus
MRUS
|
+$3.71M |
| 2 |
PVLA
Palvella Therapeutics
PVLA
|
+$2.08M |
| 3 |
KNTE
Kinnate Biopharma Inc. Common Stock
KNTE
|
+$1.32M |
| 4 |
Structure Therapeutics
GPCR
|
+$540K |
| 5 |
PRDS
Pardes Biosciences, Inc. Common Stock
PRDS
|
+$525K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Cabaletta Bio
CABA
|
+$3.48M |
| 2 |
CBAY
Cymabay Therapeutics
CBAY
|
+$2.27M |
| 3 |
BLU
BELLUS Health Inc.
BLU
|
+$1.76M |
| 4 |
WHWK
Whitehawk Therapeutics
WHWK
|
+$831K |
| 5 |
THRX
Theseus Pharmaceuticals, Inc. Common Stock
THRX
|
+$225K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
ALPN
1
DELISTED
Alpine Immune Sciences Inc
ALPN
| $24.2M | 20.18% |
3,136,173
+10,000
| +0.3% | +$79.7K |
|
|
2
Cabaletta Bio
CABA
$439M
| $20.3M | 16.92% |
2,454,627
-371,349
| -13% | -$3.48M |
|
|
MRUS
3
DELISTED
Merus
MRUS
| $19.6M | 16.38% |
1,067,723
+213,132
| +25% | +$3.71M |
|
|
KNTE
4
DELISTED
Kinnate Biopharma Inc. Common Stock
KNTE
| $13.8M | 11.54% |
2,214,250
+215,833
| +11% | +$1.32M |
|
|
CBAY
5
DELISTED
Cymabay Therapeutics
CBAY
| $11.9M | 9.96% |
1,369,927
-283,568
| -17% | -$2.27M |
|
|
PVLA
6
Palvella Therapeutics
PVLA
$1.98B
| $6.9M | 5.75% |
88,346
+17,989
| +26% | +$2.08M |
|
|
THRX
7
DELISTED
Theseus Pharmaceuticals, Inc. Common Stock
THRX
| $6.76M | 5.64% |
761,258
-22,900
| -3% | -$225K |
|
|
BLU
8
DELISTED
BELLUS Health Inc.
BLU
| $6.24M | 5.2% |
866,646
-227,254
| -21% | -$1.76M |
|
|
PRDS
9
DELISTED
Pardes Biosciences, Inc. Common Stock
PRDS
| $4.39M | 3.66% |
3,324,061
+320,959
| +11% | +$525K |
|
10
Passage Bio
PASG
$15.9M
| $3.26M | 2.72% |
170,380
+2,584
| +2% | +$70K |
|
11
Neurogene
NGNE
$696M
| $1.7M | 1.42% |
121,416
+6,859
| +6% | +$80.4K |
|
|
12
Structure Therapeutics
GPCR
$3.49B
| $547K | 0.46% |
+23,000
| New | +$540K |
|
13
Pharvaris
PHVS
$2.39B
| $211K | 0.18% |
26,225
+900
| +4% | +$7.92K |
|
|
WHWK
14
Whitehawk Therapeutics
WHWK
$183M
| – | – |
-64,739
| Closed | -$831K |
|
Similar funds
SWM
RFA
WA
AMM
EIM
SWP
ACM
BI
Lynx1 Capital Management's Q1 2023 Portfolio in Review
As of Q1 2023, Lynx1 Capital Management held 14 positions worth $120M, up 3.7% from $116M the previous quarter. Its ten largest holdings account for 98% of the portfolio.
Lynx1 Capital Management's Q1 2023 filing shows 1 new, 8 increased, 4 reduced and 1 closed positions. Its largest new stake was Structure Therapeutics: 23,000 shares worth $547K. The largest sale was Cabaletta Bio, an estimated $3.48M.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.
- Lynx1 Capital Management's largest Q1 2023 buy was Structure Therapeutics: 23,000 shares worth $547K.
- Lynx1 Capital Management added most to Merus in Q1 2023, an estimated $3.71M increase.
- Lynx1 Capital Management's biggest Q1 2023 reduction was Cabaletta Bio, cutting an estimated $3.48M.
- Lynx1 Capital Management fully exited Whitehawk Therapeutics in Q1 2023, selling an estimated $831K.
- Lynx1 Capital Management's ten largest holdings make up 98% of its $120M portfolio in Q1 2023.
- Lynx1 Capital Management opened 1 new position and closed 1 in Q1 2023.
- Lynx1 Capital Management's portfolio value rose 3.7% quarter-over-quarter to $120M.
Based on Lynx1 Capital Management's 13F filing for Q1 2023, filed 15 May 2023.